Literature DB >> 32201962

A small allelic variant in donor class I MHC is sufficient to induce alloantibodies following transfusion of standard or pathogen-reduced platelets in mice.

Rachael P Jackman1,2, John W Heitman1, Marcus O Muench1,2.   

Abstract

BACKGROUND AND OBJECTIVES: Alloimmunization targeting major histocompatibility (MHC) antigens is common following platelet transfusion. Pathogen reduction of platelets can block alloimmunization to MHC in mice and induce partial antigen-specific tolerance to subsequent transfusions. This study utilized small allelic variants to evaluate the relative contributions of class I and class II MHC to the alloresponse against untreated or pathogen-reduced platelets.
MATERIALS AND METHODS: C57BL/6 (B6) Kbm1 and B6 IAbm12 mice with small variants in the class I Kb and class II IAb alleles, respectively, were used as platelet donors for wild-type B6 recipients. Both untreated and pathogen-reduced platelet-rich plasma (PRP) transfusions were evaluated for immunogenicity by measuring antibody responses and ex vivo cytokine production.
RESULTS: Both the Kbm1 and IAbm12 alleles induced antibody responses, though the response to Kbm1 was greater. Pathogen reduction blocked the antibody responses to IAbm12 , but not to Kbm1 . Both the Kbm1 and IAbm12 alleles primed ex vivo cytokine responses that were blocked with pathogen reduction, though responses to IAbm12 were broader and larger (Kbm1 responses: IFN-γ, TNFα, and MIP-1β; IAbm12 responses: IFN-γ, TNFα, IL-1β, IL-10, IL-13, and GM-CSF). Pathogen-reduced Kbm1 PRP did not appear to induce any tolerance to subsequent untreated Kbm1 PRP transfusions.
CONCLUSION: Minor allelic variants in both the class I and class II MHC are capable of inducing an alloresponse to transfusion. The Kbm1 PRP induced alloantibodies even with pathogen reduction and did not show signs of inducing the partial tolerance to subsequent transfusions observed with a larger MHC mismatch.
© 2020 International Society of Blood Transfusion.

Entities:  

Keywords:  MHC; alloimmunization; pathogen reduction

Mesh:

Substances:

Year:  2020        PMID: 32201962      PMCID: PMC7374020          DOI: 10.1111/vox.12897

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  30 in total

1.  B6.C-H-2bm12. A new H-2 mutation in the I region in the mouse.

Authors:  I F McKenzie; G M Morgan; M S Sandrin; M M Michaelides; R W Melvold; H I Kohn
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

2.  Pathogen reduction with amotosalen/UVA reduces platelet refractoriness in a dog platelet transfusion model.

Authors:  Sherrill J Slichter; S Lawrence Bailey; Irena Gettinger; Esther Pellham; Todd Christoffel; Grace Castro; Jennifer M Green; Adonis Stassinopoulos
Journal:  Vox Sang       Date:  2019-07-11       Impact factor: 2.144

3.  Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice.

Authors:  Johnson Q Tran; Marcus O Muench; John W Heitman; Rachael P Jackman
Journal:  Vox Sang       Date:  2019-02-07       Impact factor: 2.144

4.  Pathogen reduction with riboflavin and ultraviolet light induces a quasi-apoptotic state in blood leukocytes.

Authors:  Johnson Q Tran; Marcus O Muench; John W Heitman; Rachael P Jackman
Journal:  Transfusion       Date:  2019-10-10       Impact factor: 3.157

5.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

Authors:  Sherrill J Slichter; Kathryn Davis; Helen Enright; Hayden Braine; Terry Gernsheimer; Kuo-Jang Kao; Thomas Kickler; Edward Lee; Janice McFarland; Jeffrey McCullough; Glenn Rodey; Charles A Schiffer; Robert Woodson
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

6.  Functional inactivation of white blood cells by Mirasol treatment.

Authors:  Loren D Fast; Gilbert Dileone; Junzhi Li; Raymond Goodrich
Journal:  Transfusion       Date:  2006-04       Impact factor: 3.157

7.  Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation.

Authors:  S Itescu; T C Tung; E M Burke; A Weinberg; N Moazami; J H Artrip; N Suciu-Foca; E A Rose; M C Oz; R E Michler
Journal:  Circulation       Date:  1998-08-25       Impact factor: 29.690

8.  Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.

Authors:  Marcus O Muench; John W Heitman; Heather Inglis; Marina E Fomin; Susanne Marschner; Raymond P Goodrich; Philip J Norris; Rachael P Jackman
Journal:  Transfusion       Date:  2016-03-29       Impact factor: 3.157

9.  Alloimmunogenicity of an isolated MHC allele is affected by the context of MHC mismatch in a murine model.

Authors:  Krystalyn E Hudson; Andrea S L Wong; Amanda L Richards; Linda M Kapp; James C Zimring
Journal:  Transfusion       Date:  2019-01-25       Impact factor: 3.157

10.  Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation.

Authors:  J W Semple; E R Speck; Y P Milev; V Blanchette; J Freedman
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.